Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh’s National Kala-azar Elimination Programme
Authors:
- Sakhawat HossainSHSakhawat Hossain
- Amresh KumarAKAmresh Kumar
- A F M Akhtar HossainAHA F M Akhtar Hossain
- M MahshinMMM Mahshin
- Abhijit SharmaASAbhijit Sharma
- Akter HossainAHAkter Hossain
- Varun SharmaVSVarun Sharma
- Rashidul HaqueRHRashidul Haque
- A K M ShamsuzzamanASA K M Shamsuzzaman
- Shomik MarufSMShomik Maruf
- Prakash GhoshPGPrakash Ghosh
- Vivek AhujaVAVivek Ahuja
Open Access
- 13 August 2018
- journal article
- research article
- Published by Springer Nature in Infectious Diseases of Poverty
- Vol. 7 (1) , 80
Abstract
Adverse effects of antileishmanial drugs can affect patients’ quality of life and adherence to therapy for visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL). In Bangladesh, there are 26 treatment centers that manage leishmaniasis cases coming from 100 endemic upazilas (subdistricts) of 26 districts (these include VL, PKDL, treatment failure, and relapse VL and cutaneous leishmaniasis cases). This study aimed to investigate the feasibility of using focused pharmacovigilance for VL (VLPV) in Bangladesh’s National Kala-azar Elimination Programme for the early detection and prevention of expected and unexpected adverse drug reactions (ADRs). This activity has been going on since December 2014. Activity area includes secondary public hospital or Upazila health complex (UHC) in hundred sub districts and Surya Kanta Kala-azar Research Center (SKKRC) in Mymensingh District, a specialized center for management of complicated VL and PKDL cases. Communicable Disease Control (CDC) of the Directorate General of Health Services (DGHS) assigned twenty five of hundred UHCs and SKKRC (total 26) as treatment centers depending on their suitable geographical location. This was implemented for better management of VL cases with Liposomal Amphotericin B (AmBisome®) to ensure patient convenience and proper utilization of this expensive donated drug. A VLPV expert committee and a UHC VLPV team were established, an operational manual and pharmacovigilance report forms were developed, training and refresher training of health personnel took place at UHCs and at the central level, collected information such as patient data including demographics, treatment history and response, adverse events were analyzed. This report includes information for the period from December 2014 to December 2016. From December 2014 to December 2016, 1327 leishmaniasis patients were treated and 1066 (80%) were available for VLPV. Out of these, 57, 33, 9, and 1% were new VL, PKDL, VL relapse, and other cases, respectively. Liposomal amphotericin B was mostly used (82%) for case management, followed by miltefosine (20%) and paromomycin (3%). Out of the 1066 patients, 26% experienced ADRs. The most frequent ADR was fever (17%, 176/1066), followed by vomiting (5%, 51/1066). Thirteen serious adverse events (SAEs) (eight deaths and five unexpected SAEs) were observed. The expert committee assessed that three of the deaths and all unexpected SAEs were possibly related to treatment. Out of the five unexpected SAEs, four were miltefosine-induced ophthalmic complications and the other was an AmBisome®-induced avascular necrosis of the nasal alae. The Directorate General of the Drug Administration entered the ADRs into the World Health Organization Uppsala Monitoring Centre (WHO-UMC) VigiFlow database. This study found that VLPV through NKEP is feasible and should be continued as a routine activity into the public health system of Bangladesh to ensure patient safety against anti-leishmanial drugs.Keywords
Funding Information
- PATH USA
This publication has 15 references indexed in Scilit:
- Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in BangladeshPLOS Neglected Tropical Diseases, 2017
- Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, IndiaThe American Journal of Tropical Medicine and Hygiene, 2016
- Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in BangladeshPLOS Neglected Tropical Diseases, 2015
- Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility studyThe Lancet Global Health, 2014
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- Phase IV Trial of Miltefosine in Adults and Children for Treatment of Visceral Leishmaniasis (Kala-Azar) in BangladeshThe American Journal of Tropical Medicine and Hygiene, 2011
- Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasisBritish Journal of Dermatology, 2011
- Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasisTransactions of the Royal Society of Tropical Medicine and Hygiene, 2011
- Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in IndiaNew England Journal of Medicine, 2010
- Phase 4 Trial of Miltefosine for the Treatment of Indian Visceral LeishmaniasisThe Journal of Infectious Diseases, 2007